ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01152437
Recruitment Status : Completed
First Posted : June 29, 2010
Results First Posted : November 21, 2013
Last Update Posted : June 26, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
This Phase II study is open to patients with metastatic colorectal cancer who have tried but failed chemotherapy regimens containing oxaliplatin and irinotecan. Patients must not have received anti-EGFR (Epidermal Growth Factor Receptor) treatment (for example, cetuximab, panitumumab) in the past. Patients with wild-type KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) colorectal cancer will be randomised to receive either BIBW 2992 or cetuximab. Patients with KRAS mutated colorectal cancer will not be randomised, but will all receive BIBW 2992. The main objectives of the study are: to compare the effectiveness of BIBW 2992 with that of cetuximab in patients with KRAS wild type cancer, and to assess the effectiveness of BIBW 2992 in patients with KRAS mutated cancer.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Drug: BIBW 2992 Drug: Cetuximab Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment
Study Start Date : June 2010
Actual Primary Completion Date : March 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIBW 2992
Patients receive BIBW 2992 tablets once daily
Drug: BIBW 2992
Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management

Active Comparator: Cetuximab
Patients receive cetuximab intravenously once a week, every week
Drug: Cetuximab
Patients receive cetuximab intravenously, once a week, every week




Primary Outcome Measures :
  1. Percentage of Participants With Objective Response [ Time Frame: Baseline till progression or death, whichever came first, assessed up to 23 months ]
    Percentage of participants with objective response: complete response (CR) or partial response (PR) according to RECIST (version 1.1) without confirmation criteria applied.

  2. Percentage of Participants With Disease Control (DC) [ Time Frame: Baseline till progression or death, whichever came first, assessed up to 23 months ]
    Percentage of participants with objective response or stable disease (SD) as determined by RECIST (version 1.1) with confirmation criteria applied.


Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Baseline till progression or death, whichever came first, assessed up to 23 months ]
    PFS time is defined as time from randomisation (wild-type group) or start of treatment (mutated group) to tumor progression evaluated according to RECIST (version 1.1) or death whichever occurs earlier. Median and confidence interval estimated using product-limit Kaplan-Meier method.

  2. Overall Survival (OS) Time [ Time Frame: Baseline till death, assessed up to 23 months ]
    OS time is defined as time from the date of randomisation (wild-type group) or date of start of treatment (mutated group) to the date of death. Median and confidence interval estimated using product-limit Kaplan-Meier method.

  3. Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 8 (Cpre,ss,8) [ Time Frame: day 8 ]
    Cpre,ss,8 represents the pre-dose concentration of afatinib in plasma at steady state on day 8.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Patients with metastatic colorectal cancer who have failed both oxaliplatin- and irinotecan-based regimens
  2. Tumour sample available for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation testing and other biomarker analyses.

Exclusion criteria:

  1. Prior treatment with Epidermal Growth Factor Receptor (EGFR) targeting small molecules or antibodies.
  2. Biological treatment (including Bevacizumab or any other antiangiogenic agents) during the trial is not allowed.
  3. Known pre-existing interstitial lung disease.
  4. Planned major surgical procedures during the trial period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01152437


Locations
United Kingdom
1200.74.44001 Boehringer Ingelheim Investigational Site
Bournemouth, United Kingdom
1200.74.44005 Boehringer Ingelheim Investigational Site
Bristol, United Kingdom
1200.74.44006 Boehringer Ingelheim Investigational Site
Cambridge, United Kingdom
1200.74.44003 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
1200.74.44009 Boehringer Ingelheim Investigational Site
London, United Kingdom
1200.74.44012 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
1200.74.44007 Boehringer Ingelheim Investigational Site
Northwood, United Kingdom
1200.74.44013 Boehringer Ingelheim Investigational Site
Nottingham, United Kingdom
1200.74.44011 Boehringer Ingelheim Investigational Site
Poole, United Kingdom
1200.74.44010 Boehringer Ingelheim Investigational Site
Sheffield, United Kingdom
1200.74.44008 Boehringer Ingelheim Investigational Site
Southampton, United Kingdom
1200.74.44004 Boehringer Ingelheim Investigational Site
Sutton, Surrey, United Kingdom
1200.74.44002 Boehringer Ingelheim Investigational Site
Truro, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01152437     History of Changes
Other Study ID Numbers: 1200.74
2009-011996-59 ( EudraCT Number: EudraCT )
First Posted: June 29, 2010    Key Record Dates
Results First Posted: November 21, 2013
Last Update Posted: June 26, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Cetuximab
Antineoplastic Agents